Latest News Releases From The Newsroom
Keybanc Sees Opportunity On AMD, AppFolio, AvidXchange, and Ameren
June 12th, 2023
Advanced Micro Devices, Inc. (Nasdaq: AMD), a leading semiconductor company specializing in advanced computing and graphics technologies, saw its price target raised by KeyBanc from $110 to $150. With $AMD closing at $124.92 on Friday, this . Read more
Pharvaris: Potential On-Demand HAE Treatment; Novartis Is To Takeover Chinook Therapeutics
June 12th, 2023
Pharvaris N.V. (Nasdaq: PHVS) released data from their Phase 2 study, RAPIDe-1, evaluating the on-demand treatment of hereditary angioedema (HAE) attacks with PHVS416 (deucrictibant immediate-release capsules). The study showed that treatment with. Read more
Intellia Therapeutics and Ocular Therapeutix: Promising Trial Data for HAE and Wet AMD
June 11th, 2023
Intellia Therapeutics, Inc. (Nasdaq: NTLA) has shared updated interim results from the Phase 1 portion of their ongoing study of NTLA-2002, a CRISPR candidate for treating hereditary angioedema (HAE). The company believes that the data reinf. Read more
Quarterly Results Ahead: Adobe, Kroger, Jabil, and Cognyte Reports Coming
June 10th, 2023
Thursday, June 15, will see several companies releasing their financial results, including: Adobe Inc. (Nasdaq: ADBE), a global leader in digital media and marketing solutions, is set to announce its second-quarter fiscal year 2023 results after t. Read more
Earnings Figures Preview: Lennar, Anterix, Aurora Cannabis, and High Tide
June 10th, 2023
Several companies are expected to report their financial results on Wednesday, June 14, including: Lennar Corporation (NYSE: LEN)(NYSE:LEN.B), a leading home construction and real estate development company, is set to announce its second-qua. Read more
Biogen: FDA Panel Backs OK of Alzheimer's Drug; Disc Medicine: Upgraded, Promising Trial Data
June 10th, 2023
Eisai and Biogen's (Nasdaq: BIIB) Alzheimer's drug candidate, LEQEMBI (lecanemab-irmb), received unanimous support from FDA PCNS panel based on Phase 3 Clarity AD trial data. The committee acknowledged its clinical benefit, overall benefit-r. Read more
GE Awarded up to $422.81M Contract; Primerica, CRISPR, Cineverse and Corning: PT Hiked
June 10th, 2023
General Electric Company's (NYSE: GE) subsidiary, GE Aerospace, has secured a significant contract from the Defense Logistics Agency Aviation for supplies related to the F-series engines (F101/110/118). The firm-fixed price, requirements-typ. Read more
23andMe: Strategic Move; Oracle, Tesla and Microsoft: PT Boost Hint at Potential Upsides
June 09th, 2023
23andMe Holding Co. (Nasdaq: ME), a leading genetic testing and personal genomics company, has disclosed in a regulatory filing with the SEC a reduction in force involving around 75 employees, representing approximately 9% of its workforce. . Read more
Pfizer to End License Deal with Theravance Bio; Truist Bullish On Vail Resorts and Leonardo DRS
June 09th, 2023
Theravance Biopharma Ireland Limited, an affiliate of Theravance Biopharma, Inc. (Nasdaq: TBPH), entered into a global license agreement with Pfizer Inc. (NYSE: PFE) in December 2019 for its preclinical skin-selective, locally acting pan-JAK inhibito. Read more
Aehr Test Systems Gets $13.7M in Orders; Fisker Targets Chinese Market
June 09th, 2023
Aehr Test Systems (Nasdaq: AEHR) has secured significant orders worth $13.7 million from a leading Fortune 500 semiconductor device supplier, who is a major player in the automotive semiconductor market. The orders are for Aehr's WaferPak fu. Read more
Want To Find Some News?
News By Industries
Recent Posts
-
NJCP National Football Conference Names David Dalton Head Coach of Salt Lake Yeti
February 06th, 2026FDA Takes New Approach to "No Artificial Colors" Claims
February 06th, 2026NJCP National Football Conference Announces Micah Deckart as Head Coach of the Idaho Outlaws
February 05th, 2026
Member Login